Humana (HUM) Dividend Yield & History

HUM$385.70-57.63 -13.00%
Medical - Healthcare PlansLarge Cap
Compare
Market cap$46.32BEnterprise value$59.62BRevenue (TTM)$154.19BMarket positionTop 25%

Score

35
Bearish
Value
39
Quality
37
Growth
28
$385.70Price
$46.32BMarket cap
42.47P/E
9.99Forward P/E
0.69%Dividend yield

Yield is based on dividends paid in the past 12 months. 2026 isn't counted in streaks until the year ends.

A 0.69% yield at $385.70 follows $2.66 a share paid by Humana Inc. over the past year.

Humana raised its yearly dividend in 4 of the last 5 years.

Humana raised its quarterly dividend from $0.79 to $0.89 on 30 March 2023, up 12.4%.

In the past year, 34% of Humana earnings was paid as a dividend.

The Humana dividend is quarterly.

Humana next goes ex-dividend on 24 December 2026. Cash is due on 29 January 2027.

7.9% a year is the five-year dividend growth rate at Humana.

Our records cover 108 payments from 1982 to 2026.

At today's yield, $10,000 invested would receive about $69 a year in dividends before tax, if payments stay the same. Dividends can be cut.

Learn: How to read a dividend

Full HUM quote · Forecast · Academy

Questions

When did HUM last raise the dividend?

Dated 30 March 2023, the new amount is $0.89 against $0.79.

How often does HUM pay a dividend?

The past year included 3 Humana dividends.

How many years has HUM raised the dividend?

In 4 of the last 5 years. 2025 totalled $3.54 a share.

What is the HUM dividend yield?

The dividend yield at Humana is 0.69%.

How long after the HUM ex-dividend date is the cash paid?

36 days.

Humana (HUM) Dividend Yield & History

HUM price $385.70 -57.63 -13.00%

Ticker
HUM
Price
$385.70
Change
-57.63 -13.00%
Market cap
$46.32B
P/E
42.47
Forward P/E
9.99
Dividend yield
0.79%
Beta
0.74
Sector
Healthcare
Industry
Medical - Healthcare Plans
Stocklytics score
35
Value
39
Quality
37
Growth
28

Stocklytics score rationale: value 39, quality 37, growth 28.

AI Score 65. Humana Inc. has a market cap of $49.77 billion and a price of $414.5, but its high price-to-earnings ratio of approximately 39 indicates potential overvaluation

Insights · Dividends · Forecast · Financials · Learn

Stocklytics home · Screener